Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II/III Randomized, Controlled Clinical Study of AlloStim(R) vs Physician's Choice in Asian Subjects With Advanced Hepatocellular Carcinoma

NCT05033522 is registered in ClinicalTrials.gov with Mirror Biologics, Inc. as lead sponsor.

NCT NCT05033522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05033522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II/III Randomized, Controlled Clinical Study of AlloStim(R) vs Physician's Choice in Asian Subjects With Advanced Hepatocellular Carcinoma
Lead sponsor
Mirror Biologics, Inc.
Phase
Phase 2/3
Overall status
Suspended
Start date
August 1, 2023
Completion date
December 1, 2026
Enrollment
150 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma